Patents by Inventor Rinpei Niwa
Rinpei Niwa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130295045Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: ApplicationFiled: June 17, 2013Publication date: November 7, 2013Inventors: Kenya SHITARA, Rinpei NIWA, So OHTA, Yuka SASAKI, Junji KANAZAWA, Toshihiko ISHII, Shiro AKINAGA
-
Patent number: 8492526Abstract: Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: June 22, 2011Date of Patent: July 23, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Patent number: 8491902Abstract: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.Type: GrantFiled: December 3, 2004Date of Patent: July 23, 2013Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Rinpei Niwa, So Ohta, Yuka Sasaki, Junji Kanazawa, Toshihiko Ishii, Shiro Akinaga
-
Publication number: 20130177944Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: January 31, 2013Publication date: July 11, 2013Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Tomoaki NAKAGAWA, Sayaka HORI, Rinpei NIWA, Tsuguo KUBOTA, Kazuhiro MASUDA, Kazuyasu NAKAMURA
-
Patent number: 8399621Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: December 28, 2009Date of Patent: March 19, 2013Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tomoaki Nakagawa, Sayaka Hori, Rinpei Niwa, Tsuguo Kubota, Kazuhiro Masuda, Kazuyasu Nakamura
-
Publication number: 20120276090Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: ApplicationFiled: June 8, 2012Publication date: November 1, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya SHITARA, Nobuo HANAI, Emi SHOJI, Mikiko SAKURADA, Akiko FURUYA, Kazuyasu NAKAMURA, Rinpei NIWA, Kenji SHIBATA, Motoo YAMASAKI
-
Patent number: 8197814Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: GrantFiled: January 8, 2010Date of Patent: June 12, 2012Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
-
Publication number: 20120022238Abstract: Disclosed are a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: June 22, 2011Publication date: January 26, 2012Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Kenya SHITARA, Rinpei NIWA, Akito NATSUME
-
Publication number: 20120020962Abstract: The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.Type: ApplicationFiled: September 6, 2011Publication date: January 26, 2012Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Ryuzo UEDA, Kenya SHITARA, Shiro AKINAGA, Rinpei NIWA, Masamichi KOIKE
-
Publication number: 20120010387Abstract: Among N-glycoside-linked sugar chains which are bound to the Fc region of an antibody, sugar chains which are bound to Asn at position 297 relates to the activity and stability of the antibody in blood, but there is a possibility that extra sugar chains bound to the amino acid residues at positions other than 297 have influences upon the antibody constant region-mediated activity and a possibility of causing a problem of uniformity as a therapeutic antibody preparation. Accordingly, among N-glycoside-linked sugar chains which bind to the Fc region of the antibody, a method for controlling extra sugar chains which are bound to Asn residues at positions other than position 297 according to the EU index is required.Type: ApplicationFiled: March 2, 2011Publication date: January 12, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Rinpei NIWA, Mami TSUCHIYA
-
Publication number: 20110236374Abstract: The present invention relates to a genetically recombinant antibody composition which specifically binds to ganglioside GM2, which has higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: January 24, 2008Publication date: September 29, 2011Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Patent number: 7994290Abstract: The present invention relates to a recombinant antibody composition which is a human IgG1 antibody, comprises a CH2 domain in which amino acids at positions 276 and 339 indicated by the EU index as in Kabat, et al. are replaced by other amino acids and has more improved complement-dependent cytotoxic activity than an antibody comprising a CH2 domain before the amino acids are replaced; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the DNA into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: January 24, 2008Date of Patent: August 9, 2011Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Patent number: 7923538Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: GrantFiled: July 24, 2006Date of Patent: April 12, 2011Assignee: Kyowa Hakko Kirin Co., LtdInventors: Kenya Shitara, Rinpei Niwa, Akito Natsume
-
Publication number: 20110009600Abstract: The present invention relates to a recombinant antibody composition having higher complement-dependent cytotoxic activity than a human IgG1 antibody and a human IgG3 antibody, wherein a polypeptide comprising a CH2 domain in the Fc region of a human IgG1 antibody is replaced by a polypeptide comprising an amino acid sequence which corresponds to the same position of a human IgG3 antibody indicated by the EU index as in Kabat, et al.; a DNA encoding the antibody molecule or a heavy chain constant region of the antibody molecule contained in the recombinant antibody composition; a transformant obtainable by introducing the recombinant vector into a host cell; a process for producing the recombinant antibody composition using the transformant; and a medicament comprising the recombinant antibody composition as an active ingredient.Type: ApplicationFiled: July 2, 2010Publication date: January 13, 2011Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya SHITARA, Rinpei Niwa, Akito Natsume
-
Publication number: 20100310573Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: December 28, 2009Publication date: December 9, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Tomoaki NAKAGAWA, Sayaka HORI, Rinpei NIWA, Tsuguo KUBOTA, Kazuhiro MASUDA, Kazuyasu NAKAMURA
-
Publication number: 20100221178Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: ApplicationFiled: January 8, 2010Publication date: September 2, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya SHITARA, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
-
Publication number: 20100150917Abstract: The present invention relates to the method for depleting in vivo regulatory T cell, the method for suppressing IL-10 producing activity of regulatory T cell, the method for treating diseases in which pathologic conditions are deteriorated by regulatory T cell and the method for enhancing tumor immunity which comprises administering to a patient a monoclonal antibody which specifically binds to human CC chemokine 4 (CCR4) or the antibody fragment thereof.Type: ApplicationFiled: October 5, 2009Publication date: June 17, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Ryuzo UEDA, Kenya Shitara, Shiro Akinaga, Rinpei Niwa, Masamichi Koike
-
Patent number: 7691568Abstract: A medicament for treating a patient who cannot be cured with a medicament comprising as an active ingredient an antibody composition produced by a cell unresistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex N-glycoside-linked sugar chain, which comprises as an active ingredient an antibody composition produced by a cell resistant to a lectin which recognizes a sugar chain in which 1-position of fucose is bound to 6-position of N-acetylglucosamine in the reducing end through ?-bond in a complex N-glycoside-linked sugar chain, and a method for screening the patient by using the medicament.Type: GrantFiled: April 9, 2003Date of Patent: April 6, 2010Assignee: Kyowa Hakko Kirin Co., LtdInventors: Rinpei Niwa, Kenya Shitara
-
Patent number: 7666418Abstract: A recombinant antibody or the antibody fragment thereof which specifically reacts with an extracellular domain of human CCR4; a DNA which encodes the recombinant antibody or the antibody fragment thereof; a method for producing the recombinant antibody or the antibody fragment thereof; a method for immunologically detecting CCR4, a method for immunologically detecting a cell which expressed CCR4 on the cell surface, a method for depleting a cell which expresses CCR4 on the cell surface, and a method for inhibiting production of Th2 cytokine, which comprise using the recombinant antibody according or antibody fragment thereof; a therapeutic or diagnostic agent for Th2-mediated immune diseases; and a therapeutic or diagnostic agent for a blood cancer.Type: GrantFiled: March 31, 2005Date of Patent: February 23, 2010Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Kenya Shitara, Nobuo Hanai, Emi Shoji, Mikiko Sakurada, Akiko Furuya, Kazuyasu Nakamura, Rinpei Niwa, Kenji Shibata, Motoo Yamasaki
-
Publication number: 20090226399Abstract: In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.Type: ApplicationFiled: April 8, 2009Publication date: September 10, 2009Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Kenya Shitara, Rinpei Niwa, Junji Kanazawa, Masao Asada